t o all of the myeloid lineages and frequently some B cells.
From such observations it has been inferred that the initial BCR-ABL gene rearrangement event occurs in a pluripotent hematopoietic stem cell and that the clone subsequently generated is maintained by a subpopulation of neoplastic, BCR-ABL-expressing cells that retain at least some of the defining properties of normal hematopoietic stem cells. To test this hypothesis directly, we isolated various subpopulations of CD34' cells from fresh or cryopreserved samples of peripheral blood from 5 CML patients with high white blood cell counts, 4 of which were selected because of their exclusive content of Ph+ progenitors (both colony-forming cells and long-term culture-initiating cells [LTC-IC] ). Cells in each of the CD34+ subpopulations isolated were examined for the presence of BCR-ABL mRNA using a reverse transcriptase-HRONIC MYELOID Leukemia (CML) is a malignant disorder of the hematopoietic system with a number of characteristic molecular, biological, and clinical features.' These include the presence of an abnormally expanded multilineage clone of hematopoietic cells marked by the presence of a unique BCR-ABL fusion gene. The creation of this fusion gene is the outcome of a translocation event in which 3' c-ABL sequences from chromosome 9 replace 3' sequences of the BCR-l gene on chromosome 22 usually leading to the appearance of the Philadelphia (Ph) chromosome in all daughter cells. Although the exact breakpoints associated with this gene rearrangement vary between patients (ie, between individual clones), the 8.5 kb BCR-ABL mRNA produced is the same. The result is the appearance in BCR-ABL'Ph+ cells of a cytoplasmic 210 kD protein with greater tyrosine kinase activity than the normally nuclear c-ABL gene Gene transfer studies have shown that the BCR-ABL gene can have oncogenic activity in primary murine hematopoietic cells' and comparable effects on a variety of intracellular signalling molecules in cells from CML patients and in BCR-ABL transfected cell lines have polymerase chain reaction technique that reproducibly gave a positive signal from single K562 cells. BCR-ABL mRNA was detected in 117 of 147 samples (80%) in which actin mRNA was demonstrable. This included 60% t o 90% of a large number of individually analyzed CD34+ cells including 46 single CD34+CD71XD38-cells and 27 single CD34'CD71+CD38' cells from 3 patients. In 2 of these cases, the same populations also contained a very high frequency of Ph' LTC-IC. Our findings demonstrate BCR-ABL gene expression in neoplastic cells with functional as well as surface marker characteristics of very primitive normal hematopoietic cells. This implicates the BCR-ABL gene product directly in the acquisition by these cells of properties that alter their interactions with the microenvironment and deregulate their proliferation control. 0 1996 b y The American Society of Hematology. also been described."" Nevertheless, the precise mechanisms by which BCR-ABL transforms hematopoietic cells remain poorly understood.
The presence in CML patients of multiple types of BCR-ABL'IPh' hematopoietic cells including B lymphoid as well as erythroid, megakaryocytic, and granulopoietic cells suggests that the initial gene rearrangement occurs in a cell with all of these differentiation potentialities.'* An additional feature of the neoplastic clone in CML patients is its capacity to outcompete the residual normal hematopoietic cells and take over the production of most of the mature blood cells.12 The observed prevalence in most patients of BCR-ABL'Ph' colony-forming cells (CFC)'3.'4 suggests that this phenomenon of clonal dominance occurs at a relatively early stage of hematopoietic cell differentiation, which is likely to be related to the deregulated cycling activity acquired by primitive BCR-ABL+/Ph+ cells.'5.'' Whether this is accompanied by an enlargement of the stem cell compartment in CML patients that might be anticipated to result from an ability of the BCR-ABL'Ph' stem cell population to expand abnormally is less clear because the size and turnover kinetics of the normal hematopoietic stem cell population under homeostatic conditions remains undefined. Studies using the longterm culture-initiating cell (LTC-IC) assay,"^" as well as clinical findings'"-*' and recent studies of the genotypes of hematopoietic cells regenerated in immunodeficient mice transplanted with cells from CML patients,23 all indicate that the development of CML (and even its usual treatment) is accompanied by an expansion of BCR-ABL'Ph' cells with all of these functional properties.
However, a substantial, often still predominant, normal (BCR-ABL-IPh-) stem cell population is usually maintained despite a suppression of later stages of normal hematopoiesis. Nevertheless, even though the absolute number of BCR-ABL+IPh' LTC-IC may not have expanded to exceed the size of the normal LTC-IC compartment, abnormalities have been identified both in the self-renewal behavior of these cells" and in their cycling properties." Such findings strongly suggest that the BCR-ABL gene product is active in neoplastic cells with properties (accelerated phase) *All metaphases from the CFC examined cytogenetically from all 5 patients were Ph'. t Values shown as less than the number indicated reflect the sensitivity of the measurements, ie, no metaphases of the genotype indicated were detected and, given the number analyzed, the number of LTC-IC of the genotype shown would not have been higher than the value indicated.
characteristic of very primitive normal hematopoietic cells. On the other hand, they do not exclude the possibility that such effects could be mediated indirectly as a result of the expression of BCR-ABL in later cell types. Interestingly, recent studies have reported that BCR-ABL mRNA expression in different types of BCR-ABL' cells is not u N f~r m~~*~~ and may even be subject to regulation by cytokine treatment.= This unresolved issue of where and how BCR-ABL gene expression may be regulated is of key importance, not only to obtain a better understanding of the biology of CML, but also to enable the design of improved therapeutic strategies that seek to specifically target the product 
MATERIALS AND METHODS
Primary cells. Leftover material from heparinized blood samples obtained as part of the routine diagnostic assessment of 5 Ph+ CML patients with high white blood cell ( W C ) counts was made available for these studies with informed patient consent. Additional information about the patients and the progenitor findings (results of CFC and LTC-IC analyses) on these samples are given in Table 1 . Three of the 5 patients had newly diagnosed chronic phase disease at the time the samples studied were taken. The other 2 patients were considered to be in accelerated phase. Four of the 5 patients studied were specifically selected because their CFC and LTC-IC had been previously shown to be exclusively Ph' thus minimizing any potential contamination of the CD34' populations to be studied with residual normal (Ph-) cells?' Blood was centrifuged on FicollHypaque (Pharmacia, Piscataway, NJ) to isolate light density cells (< 1.077 g/mL) and, whenever possible, the cells were then separated further and RNA isolated either directly, or after overnight storage of the cells at 4°C in Iscove's medium containing 50% fetal calf serum (FCS; StemCell Technologies, Vancouver, BC). Aliquots of light density cells were also routinely cryopreserved in a dimethyl sulfoxide-containing medium and kept at -135°C for additional studies. Heparinized normal marrow aspirate cells were obtained with informed consent either from normal individuals donating marrow for allogeneic bone marrow transplantation or from cadaveric organ donors.
Cell lines.
Ph' K562 cells3' and Ph-HL-60 cellsg2 obtained from the American Type Culture Collection (Rockville, MD) and propagated in RPM1 medium (Stemcell) containing 10% FCS were used as positive and negative controls, respectively, in the BCR-ABL RT-PCR analyses.
Isolation of subpopulations. "Fresh" (usually 1 day old) or thawed (washed) cells were washed again in phosphate-buffered saline containing 2% FCS and then resuspended in Hank's hepesbuffered salt solution containing 2% FCS and 0.1% sodium azide (HFN). Cells were then incubated at S lo7 cells/mL with IgGl monoclonal antibodies (MoAbs) specific for CD34 (8G12-Cy5), CD71 (OKT9-FITC) and either CD38 (Leul7-PE; Becton Dickinson, San Jose, CA) HLA-DR (Becton Dickinson) or T~Y -I -P E~~ at 10, 1, 2.5, 5, and 5 mg/mL, respectively, for 30 minutes at 4°C. Cells were then washed once in HFN and once in HFN containing 2 mg/mL propidium iodide (PI; Sigma Chemical CO, St Louis, MO) and resuspended in Hanks' HEPES-buffered salt solution containing 2% FCS (HF) before sorting. Throughout the staining procedure, cells were kept at 4°C. Cells with medium-high forward light scattering characteristics, low side scattering characteristics and a CD34' phenotype were sorted into subpopulations expressing different levels of CD71, CD38, and Thy-l, respectively, using a FACStar' (Becton Dickinson) equipped with a 5-W argon laser and a heliumneon laser as indicated in Fig 3. Positivity was defined as fluorescence that exceeded at least 99% of that obtained with an irrelevant control IgGl MoAb and, for CD38 positivity, an even more stringent gate was used, as illustrated (see Fig 3) . Sorted cells were collected in Eppendorf tubes containing LTC-medium (HCC-5 100, Stemcell) and then used for RNA and progenitor analyses as described later.
Progenitor assays. CFC assays were performed by plating appropriate numbers of cells (estimated to give 5 100 colonies per 1 mL culture) in methylcellulose medium (Stemcell) supplemented with the following recombinant human growth factors: Steel factor (SF, 50 n@mL), interleukin-3 (IL-3, 20 ng/mL), IL-6 (20 ng/mL), granulocyte-macrophage colony stimulating factor (GM-CSF, 20 ng/ mL), G-CSF (20 ng/mL), and erythropoietin (Ep, 3 U/mL). These cultures were then incubated for 16 days at 37°C to allow the development of erythroid, granulopoietic and multilineage colonies from colony-forming units (Cm)-erythroid, burst forming units-erythroid, CFU-granulocyte macrophage (CFU-GM) and CFU-granulocyte erythroid macrophage megakaryocyte (Cm-GEMM), respectively. Cells from the same original suspensions were also assayed for LTC-IC by plating appropriate aliquots on preestablished irradiated mouse fibroblasts genetically engineered to produce human IL-3 (10 ng/mL) human G-CSF (130 ng/mL> and human SF (10 ng/ Pst cDNA fragment sGCTGAAGGGCTTCTTCCTTATTGATG3'
1.8 kb mL) and then maintaining these cultures at 37°C for 6 weeks in LTC medium supplemented with freshly dissolved mol/L hydrocortisone sodium hemisuccinate (Sigma) with weekly exchanges of half the medium and removal of half the nonadherent cells. At the end of the 6-week period of culture, the nonadherent cells from each LTC-IC assay culture were combined with the corresponding trypsinized adherent cells and assayed for their CFC content by plating them in methylcellulose cultures as previously described. The relative number of LTC-IC present in the original input suspension was then calculated by dividing the total number of CFC detected in the 6-week harvest by 8.34. 35 CFC and LTC-IC were genotyped as Ph+ or Ph-by cytogenetic analysis of Giemsa-banded metaphases prepared from colonies generated in the direct CFC assays and in the CFC assays performed on the 6-week LTC-IC culture harvests, respectively."j RNA analyses. To evaluate mRNA expression in samples of carefully under an inverted microscope, were selected for further processing. To maximize transfer of the cellular contents of each well into the PCR reaction, 25 pL of denaturing solution (5 molL guanidine isothiocyanate, GIT, containing 25 mmol/L sodium citrate, pH = 7, 0.5% sarcosyl and 20 mmol/L 1, 4-dithioerythritol, D m ) was first added to each well selected and the mixture then transferred to a 0.5 mL PCR tube followed by a second rinse of the same well with another 25 pL of denaturing solution (such that the final solution always contained at least 4 mol/L GIT). The occasional well in which any cell(s) were left behind (as evident from a final check under the microscope) was discarded from subsequent analysis. Nucleic acids were precipitated by the addition of 7.5 m o m ammonium acetate containing 1.5 mg/mL glycogen (Boehringer Mannheim, Mannheim, Germany). Total mRNA was then reverse transcribed into cDNA using Super Script I1 reverse transcriptase (GIBCO-BRL, Gaithersburg, MD) and an oligo-dT primer (Oligo, Etc, Portland, OR) ( Table 2 ). The cDNA was precipitated in the presence of a linear polyacrylamide carrier and then polyadenylated using the terminal deoxytransferase (GIBCO-BRL). The first PCR was performed using the same oligo-dT primer as for the cDNA synthesis in a final volume of 50 FL.~' Briefly, the total volume of the polyA cDNA was mixed with the PCR buffer (10 mmol/L Tris pH 8.8, 50 m m o K KCI, and 5 mmoYL MgCL2) containing 10 mg/mL of nuclease-free bovine serum albumin (BSA), Triton X-100 (Sigma), and 1 mmol/L of dCTP, dTTP, and dGTP (Pharmacia); Taq Pol (GIBCO-BRL) and 80 pglpL of gene p32 protein (Pharmacia). This reaction mix was overlaid with 100 pL of mineral oil (Sigma) and then amplified for 45 cycles (30 seconds at 94"C, 2 minutes at 55°C and 10 minutes 72°C). In initial experiments aliquots of 1 to 5 pL of the amplified total cDNA were then subjected to a second round of PCR amplification in 50 pL volumes of 1 X Taq buffer (GIBCO-BRL) containing 1.5 mmoVL MgCL2, 1 mmoVL of each dNTP (Pharmacia) and 15 pmol of specific primers (Table 2 ) designed to amplify sequences of either BCR-ABL mRNA or actin mRNA. Later on, 1 to 5 pL of the total cDNA from the first PCR amplification step was used as a template for the further coamplification of BCR-ABL and actin cDNAs in the same tube. The PCR conditions for this coamplification step were optimized for the primer concentrations and ratios, temperatures of annealing and number of cycles as previously described.3x We then added an aliquot of the total cDNA product to the PCR mixture (20 mmoVL, Tris-HCI pH 8.4, 50 mmoYL KCI, 1.5 mmol/L MgClz, 0.5 mmol/L each dNTP, 1 to 2 U Taq Pol, 0.1 mg/mL BSA and 0.3 pmoYpL of each of the primers described in Table 2 ). Thirty-five cycles (94°C for 30 seconds, 60°C for 30 seconds, 72°C for 1 minute) were then repeated. The expected products were visualized after electrophoresis on a 2% agarose gel followed by alkaline transfer to an ionic nylon membrane (Zetaprobe; BioRad, Hercules, CA) and hybridization using a BCR-ABL or an actin probe (Table 2) as described later. Southern blot analysis of total ampl$ed cDNA. Ten milliters of the total amplified cDNA was electrophoresed in a 1% agarose gel and passively transferred overnight onto an ionic nylon membrane. The actin probe was labeled with "P-dCTP by random priming and purified on a Sephadex-G50 column before hybridization. Blots were hybridized for 20 hours at 60°C in 6 X saline sodium citrate (SSC), deionized formamide, 2 mmom EDTA, 1% slum milk, 500 mg/L salmon sperm DNA and 1% sodium dodecyl sulfate (SDS). Membranes were washed twice at 60°C in a solution of 0.3 X SSC, 0.1% SDS and 1 mg/mL sodium pyrophosphate and the blots exposed to Kodak XAR film (Eastman-Kodak, Rochester, NY) at -70°C for periods of from 1 to 7 days. neously run negative controls (extracts of 1,000 HL60 cells, lane 3; or 1,000 K562 cells, treated identically but without addition of RT, lane 12) showing a lack of contamination of any part of the reaction by genomic DNA. The PCR product generated from this initial amplification of all cDNAs was then subjected to a second PCR step using different sets of primers specific for RCR-ARL mRNA as also described in Materials and Methods. This latter step yielded an obvious BCR-ABL-specific signal for extracts of I O or more K562 cells, with questionable results for extracts of single K562 cells (data not shown). However, after transfer and hybridization with a RCR-ARL probe, a signal could be readily shown in products generated from single K562 cells with the set of BCR-ABL primers used in these pilot studies. Specificity was shown by the lack of a signal when the product of the water control from the first PCR was subjected to the same second PCR reaction as the test samples.
RESULTS

Development
To provide an internal positive control for the procedure, the conditions of the second PCR step were modified to optimize the coamplification and detection of sequences derived originally from actin as well as RCR-ARL mRNAs (see Materials and Methods). As illustrated in Fig 2, this modified procedure allowed the specific detection of actin as well as RCR-ABL mRNA sequences in single K562 cells. Moreover, the procedure appears semi-quantitative in terms of the differences in signal intensity obtained from 1.000, 100, IO, and single K562 cells. Negative controls included water or RNA processed in the absence of RT to ensure the absence of contamination of any part of the reaction. In addition. RNA extracted from HL60 cells and processed in parallel with the K562 RNA consistently showed amplification with the actin primers but not with the BCR-ARL primers.
Analwis of BCR-ARL mRNA expression in different CD34' suI~p,pop~~lation.s qf CML cells. The sensitive RT-PCR technique developed using K562 cells as a model test system was then applied to highly purified subpopulations of CD34' cells isolated from samples of blood from 5 CML patients with high WBC counts. The clinical details of these patients are shown in Table I together with the results of the CFC and LTC-IC assays performed on the original light density fraction isolated from their blood samples. To minimize the possibility of obtaining Ph cells in the populations chosen for these mRNA analyses and to maximize the possibility of overlap between RCR-ARL mRNA positivity and the possession of specific progenitor properties, 4 of the CML patients studied were selected for their generally high and exclusive content of circulating Ph' CFC and LTC-IC. In the fifth patient, although all CFC were Ph' only Ph-LTC-IC were detected (see Table l ) . In addition, most of the sorted populations where CFC and/or LTC-IC were anticipated to be present,3" were also assayed for these progenitor types and their Ph' status confirmed cytogenetically. Progenitor distributions in sorted populations from some of these patients (and others) will be reported in detail elsewhere, but for the purposes of comparison with the molecular Coamplification of BCR-ABL and actin fragments from indicated numbers of K562 cells using two different sets of primers (primers 1-3 for BCR-ABL; primers A1-A2 for actin-see Table 2 for primer sequences). One milliliter of the first PCR product was used as a DNA source t o run the second PCR reaction. (A) Ten milliliters of PCR product was loaded on a 2% agarose gel, (B) then transferred and hybridized using an actin and a BCR-AB1 probe. Lane 1 contains a water control, lanes 2 t o 10 contain secondary PCR products from the amplification of a primary PCR product from K562 cells using BCR-ABL primers either alone (lane 2) or together (lanes 3 t o 10) . As indicated, lane 4 is a negative control for the cDNA synthesis and contains a sample where the PCR reaction was performed but no RT was added.
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From studies here, relevant data are included in Table 3 . Representative phenotype distributions for some of the subpopulations of CD34' cells examined for the presence of BCR-ABL transcripts are shown in Fig 3 . Table 4 summarizes the results of the RT-PCR analyses obtained for particular populations that were examined from the 5 patients studied. For several of these the populations of interest were isolated from the same original sample on 3 or 4 different occasions and then the RT-PCR analyses repeated. It can be seen that BCR-ABL mRNA was detected in all CD34' subpopulations analyzed, frequently at the single cell level. Figure 4 shows representative Southern blots of the products of PCR reactions performed in duplicate on extracts of 2,000 CD34TD7 1-Thy-1 ', CD34TD7 1 -CD38-, CD34'CD7 1 TD38' and CD34TD7 1 'CD38' cells. Amplified BCR-ABL sequences from each of these phenotypes are clearly evident. A total of 213 samples were analyzed, in 147 of which (69%) actin mRNA was detected. In 117 of these (80%), BCR-ABL mRNA was also detectable. Negative controls were included in every analysis to ensure the absence of contamination even by genomic DNA. This involved coprocessing mRNA extracted simultaneously from 1,000 HL60 cells and subjecting this material to the same procedure either with RT MAGUER-SATTA ET AL in the initial step (in which case only an actin signal was obtained) or without RT in the initial step (in which case neither an actin nor a BCR-ABL signal was obtained). In each experiment, extracts obtained from one up to 1,000 K562 cells were also processed to provide a positive control by demonstration of both actin and BCR-ABL sequences in the final reaction products.
Frequency of different types of CD34' cells containing detectable BCR-ABL transcripts. To determine the contribution of individual cells to the apparently homogeneous pattern of BCR-ABL expression in different CD34' subpopulations evident from an analysis of larger numbers of cells (and hence to examine the possibility that the results obtained might be attributable to minor contaminating cells with properties different from those representative of the population as a whole), a series of RT-PCR analyses were performed on single cells isolated from 3 of the 5 CML patients studied. In each case, up to 20 individual CD34'CD7 1 -CD38-or IO individual CD34'CD71'CD38' cells were processed and analyzed for the presence of both actin and BCR-ABL mRNA. These two populations were chosen because the CD7 I -FITC Table 4 ). The second PCR reaction was performed using the BCR-ABL primers 1-3 (see Table 2 ) and using 1 mL of the first PCR product as a source of DNA. Ten milliters of PCR product were loaded on a 2% agarose gel, then transferred and hybridized using a BCR-ABL probe ( Table 2) former represented the most enriched source of BCR-ABL'I Ph' LTC-IC and the latter an enriched source of BCR-ABL'I Ph' CFC containing no LTC-IC.'" The results of these analyses are summarized in Table 5 . Detectability of BCR-ABL mRNA in the 20 individually analyzed CD34'CD71 -CD38-cells isolated from one of the CML patients (#5) (and its absence from extracts of normal marrow cells) is shown in Fig 5 to illustrate the type of data obtained. The frequency of detecting actin mRNA in single cells from both CML (8 1%) and normal marrow (75%) sources (Table 5 ) confirms the applicability of the RT-PCR technique used for small numbers of rare cell types. Failure to achieve a 100% success rate is likely attributable to occasional losses in the repeated 1801 handling of small amounts of material, particularly in the initial phases of the procedure, and/or the presence of some damaged (nonviable) but PI-cells after thawing.jY Table 5 also shows that BCR-ABL mRNA could be specifically detected in approximately 60% to 90% of all CML cells in which an actin message was evident and that there was no obvious difference between the two phenotypically defined subpopulations of CD34' cells compared in terms of the proportion of cells in which BCR-ABL mRNA was demonstrable.
DISCUSSION
The BCR-ABL gene has been shown to have transforming potential in primary murine hematopoietic cells and these can produce a myeloproliferative syndrome with features reminiscent of human CML.' Sequences within the BCR-ABL gene which are critical for its oncogenicity in hematopoietic cells have been and a number of abnormal molecular consequences of its expression have been reported, primarily in BCR-ABL transfected cell lines.',".
However, both of these approaches are limited in their ability to address the mechanism(s) of clonal amplification that occur in patients who develop CML. This is due, at least in part, to the fact that the events of interest presumably occur in rare subpopulations of primitive progenitors whose biology and regulation may not be reproduced either in their more mature progeny or in immortalized factor-dependent or independent cell lines. In addition, model systems created by introduction of the BCR-ABL gene into target cells, either under the control of a retroviral LTR6 or a strong constitutively active promoter," have the further drawback that the subsequent timing and level of BCR-ABL expression in the genetically modified cells is regulated differently from the BCR-ABL gene that causes CML in humans.
To enable studies of BCR-ABL gene expression in specific subpopulations of CML cells with phenotypes that have been associated with primitive hematopoietic progenitor functions, we developed a sensitive RT-PCR procedure that can be reproducibly applied to individual cells. This procedure A positive cell in this case is defined as one for which both a BCR-ABL signal and an actin signal could be detected in the same PCR amplification product. A negative cell is defined as one for which a positive actin signal was demonstrable but no ECR-ABL signal was detected.
t The 8 samples studied included various numbers of cells: 8.5 x lo4, 1,000, 100 (~2 ) .
(~2 ) . 1 (~2 ) .
For personal use only. on October 23, 2017. by guest www.bloodjournal.org From was then used to analyze different populations of cells isolated from 3 CML patients in chronic phase and 2 in accelerated phase. BCR-ARL transcripts were detected in all types of CD34' cells tested. Moreover, analyses of a series of individual cells from a phenotypically defined population known to be highly enriched in its content of Ph' LTC-IC (2% to 11% pure in these studies, Table 3 ) indicate likely overlap between this functionally defined population and those found to express BCR-ABL mRNA. Not surprisingly, we found BCR-ABL transcripts were also readily detectable in CD34' subpopulations that are CD71 ' and Thy-l or CD38' and which contain BCR-ABL'IPh' LTC-IC at lower frequencies and are more highly enriched in their content of more mature progenitors detectable as BCR-ABL'IPh' CFC'" (and Table S) .
These results differ from findings from several other laboratories who failed to detect BCR-ABL mRNA in early phenotypes of CML cells."~" The most likely explanation for the apparent discrepancy between our results and those obtained in these various studies is a difference in the sensitivities of the procedures used. although the additional possibility of reduced RNA integrity in some cases cannot be ruled out. In our studies, this latter potential problem was addressed through the use and requisite demonstration of coamplification of a control mRNA species from each cell extract analyzed. Several other groups have also reported an association between the presence of BCR-ABL mRNA and DNA in similar subpopulations of CD34' cells from CML patient^."^' However. interpretation of their data was limited by the fact that the studies were performed on bulk populations of cells, which were also likely to have been genotypically heterogeneous. thus precluding associations between gene expression, genotype. and progenitor properties in individual cells.
The common presence of normal (BCR-ABL-IPh-) cells in the most primitive compartments of both blood and marrow of many CML patients poses a major problem to all molecular analyses of phenotypically defined populations. In the present experiments. this was minimized by selecting Table 2 for the primers used) from single CD34'CD71 CD38-cells from Patient # 5 or variable numbers of normal marrow cells (as indicated). In each case mRNA was extracted, amplified by the two step RT-PCR procedure and a Southern blot was then performed on the PCR products using a BCR-ABL probe (Table 21 for hybridization.
patients' samples in which Ph' CFC and LTC-IC were elevated and dominant. However, such patients are obviously not representative of even the majority of CML patients. Some caution must therefore be exercised in extrapolating beyond these findings. The use of fluorescence in situ hybridization (FISH) offers a definitive means of genotyping BCR-ABL' cells and thus should be useful for analyzing mixed populations isolated from patients with significant residual normal stem cell populations. However, FISH technology is also not 100% accurate due to the inability of some cells to be analyzed or cells that are falsely defined as positive 4x. Therefore, even the combined use of FISH and the RT-PCR procedure described here might not be sufficient to allow a meaningful data set to be obtained from a more representative spectrum of CML patients.
The presence of BCR-ABL transcripts in the most primitive populations of CML cells provides a molecular explanation for the altered biological properties that we and others have shown such cells to exhibit. These include alterations in their proliferation in their self-renewal probability," in their response to conditions that induce apoptosis in their normal counterparts,"~"~'"' in their expression of erythropoietin receptors'" and CD44?', and in their adhesive properties."." Unfortunately, virtually nothing is known about how any of these changes may be linked to specific activities of the RCR-ABL gene product, whether they may represent indirect effects. and/or whether they may be influenced by the number of BCR-ABL transcripts present. In this regard it should be noted that our studies do not preclude the possibility that BCR-ABL gene expression can change when cells differentiate and/or are stimulated with various cyt~kines.'".'~ However, a modified approach that focuses on the quantitation of transcript numbers (rather than the proportion of positive cells) will be required to address this important outstanding question. Nevertheless, the present methodology should be useful for future investigation of other genes whose expression may be altered in primitive Ph' cells and whose identification may thus help to define For personal use only. on October 23, 2017. by guest www.bloodjournal.org From the mechanisms by which the BCR-ABL gene product alters their biological properties.
